Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME
Clinical Program Leverages Quark’s RNAi Technology Fremont, California, July 30, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME). PF-4523655 is a